Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

NCT06291987 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Myeloproliferative Neoplasms

Interventions

DRUG: Ivosidenib
DRUG: Ruxolitinib

Sponsor

University of Chicago